CM
MYGN icon

CS McKee’s Myriad Genetics MYGN Stock Holding History

CS McKee’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$926K Sell
34,000
-550
-2% -$15.1K 0.08% 86
2019
Q3 		$989K Hold
34,550
– – 0.09% 81
2019
Q2 		$960K Sell
34,550
-800
-2% -$22.6K 0.08% 83
2019
Q1 		$1.17M Sell
35,350
-2,000
-5% -$60.9K 0.1% 79
2018
Q4 		$1.09M Buy
37,350
+100
+0.3% +$3.6K 0.11% 80
2018
Q3 		$1.71M Hold
37,250
– – 0.14% 74
2018
Q2 		$1.39M Sell
37,250
-3,500
-9% -$118K 0.12% 83
2018
Q1 		$1.2M Sell
40,750
-1,500
-4% -$50.8K 0.09% 87
2017
Q4 		$1.45M Sell
42,250
-400
-0.9% -$13.5K 0.11% 80
2017
Q3 		$1.54M Buy
42,650
+12,650
+42% +$361K 0.12% 77
2017
Q2 		$775K Buy
30,000
+100
+0.3% +$2.12K 0.06% 94
2017
Q1 		$574K Sell
29,900
-200
-0.7% -$3.54K 0.05% 95
2016
Q4 		$502K Buy
30,100
+5,900
+24% +$107K 0.04% 99
2016
Q3 		$498K Sell
24,200
-3,000
-11% -$76.1K 0.03% 98
2016
Q2 		$832K Sell
27,200
-30,445
-53% -$1.06M 0.04% 94
2016
Q1 		$2.16M Sell
57,645
-65,313
-53% -$2.46M 0.08% 82
2015
Q4 		$5.31M Buy
122,958
+380
+0.3% +$16.1K 0.17% 80
2015
Q3 		$4.61M Sell
122,578
-3,890
-3% -$138K 0.15% 83
2015
Q2 		$4.3M Sell
126,468
-6,430
-5% -$219K 0.12% 88
2015
Q1 		$4.71M Sell
132,898
-17,820
-12% -$638K 0.12% 87
2014
Q4 		$5.13M Sell
150,718
-61,912
-29% -$2.2M 0.12% 86
2014
Q3 		$8.2M Sell
212,630
-35,370
-14% -$1.32M 0.19% 85
2014
Q2 		$9.59M Sell
248,000
-24,390
-9% -$907K 0.2% 88
2014
Q1 		$9.31M Sell
272,390
-595,700
-69% -$18.5M 0.2% 91
2013
Q4 		$18.2M Sell
868,090
-28,240
-3% -$714K 0.36% 74
2013
Q3 		$21.1M Sell
896,330
-61,500
-6% -$1.75M 0.36% 79
2013
Q2 		$25.7M Buy
+957,830
New +$27.8M 0.44% 69

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

CS McKee's MYGN Position: Q4 2019 in Review

CS McKee reduced its Myriad Genetics (MYGN) stake by 1.6% in Q4 2019, selling an estimated $15.1K and leaving 34,000 shares worth $926K. The position accounts for 0.08% of the portfolio, ranked #86.

CS McKee first reported a position in MYGN in Q2 2013 and has held it in 27 quarters since. The position peaked at $25.7M in Q2 2013. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

  • CS McKee held 34,000 shares of Myriad Genetics worth $926K as of Q4 2019.
  • CS McKee sold 550 Myriad Genetics shares in Q4 2019, an estimated $15.1K.
  • Myriad Genetics made up 0.08% of CS McKee's portfolio in Q4 2019, its #86 holding.
  • CS McKee first reported a position in Myriad Genetics in Q2 2013 and has held it in 27 quarters since.
  • CS McKee's Myriad Genetics position peaked at $25.7M in Q2 2013.
  • 227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on CS McKee's 13F filing for Q4 2019, filed 14 Feb 2020.